The Omics! Omics! blogger wonders where the money goes when there's a major financial failure in biotech.

Dell moves a step closer to offering Linux pre-installed.

Blogging the installation of a new mass spec. What could be more fun?

CHICAGO– Chris van Ingen, president of Agilent’s Bio-Analytical Measurement division, delivered a presentation here this week at the annual Pittcon conference.

New Law Aims to Reduce Financial Risk of Developing Biothreat Tools for US Gov't   A little-known bill enacted into law at the end of last year could be a boon to biotech companies, including those using genomic technologies, develo

Shares in Bio-Rad dropped 16.8 percent for the five-day trading period ended Tuesday.

The company’ Life Science Products division, which has been around since roughly 1990, has begun selling a line of nucleic acid-extraction devices in the US that cost $1,000, which Fuji believes will entice the low end of the market. AutoGen will sell the tool in North America.

Like pharmacy benefits managers PharmaCare and Medco before it, Kaiser, the biggest managed-care group in the US, will look into genetic and environmental causes of diseases and patient response to medications.

FDA’s Final Pharmacology Labeling Guidance Will Increase Prominence of Genetic Information In Drug Labels   Hoping to highlight genetic information more prominently for prescribing physicians, the US Food and Drug Administrati

PerkinElmer last week has appointed Richard Begley vice president and general manager of its Analytical Sciences business.

CLARIFICATION

NEWSBRIEF

GW REPORTS

NEWSBRIEF

The company is targeting the instrument and related consumables and software at larger labs that are focused on time efficiency but cannot afford the more expensive liquid chromatography systems for conducting protein purification.

Because the panel’s guidelines were crafted by medical organizations and are non-binding, they represent a way for the molecular diagnostics industry to regulate certain lab-made tests on its own.

Former Applied Biosystems President Cathy Burzik has been named to the board of directors at Bausch & Lomb.

FDA’s Larry Lesko said that performing prospective, randomized clinical trials to validate dosing based on genetic factors can be prohibitively expensive, which in turn can hinder pharmacogenomic advances. “I’m afraid that if we put this standard out for every genomic test that we’ll be going nowhere fast.”

NEWSBRIEF

NEWSBRIEF

A California appeals court maintains the constitutionality of stem cell agency.

DNA analysis helps wildlife experts trace origins of contraband ivory.

Researchers find a gene whose variations correlate with performance IQ scores.

NEWSBRIEF

NEWSBRIEF